Claims for Patent: 10,597,381

Summary for Patent: 10,597,381

Title:	Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
Abstract:	The present invention provides, inter alia, a compound having the structure: ##STR00001## Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.
Inventor(s):	Stockwell; Brent R. (New York, NY), Dixon; Scott J. (New York, NY), Skouta; Rachid (New York, NY)
Assignee:	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, NY)
Application Number:	16/247,354
Patent Claims:	1. A method for treating or ameliorating the effects of a neurodegenerative disease in a subject in need thereof comprising administering to the subject an effective amount of a compound having the structure: ##STR00263## or pharmaceutically acceptable salts thereof. 2. The method according to claim 1, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's, Parkinson's, Amyotrophic lateral sclerosis, Friedreich's ataxia, Multiple sclerosis, Huntington's Disease, Transmissible spongiform encephalopathy, Charcot-Marie-Tooth disease, Dementia with Lewy bodies, Corticobasal degeneration, Progressive supranuclear palsy, and Hereditary spastic paraparesis. 3. The method according to claim 1 further comprising co-administering to the subject an effective amount of one or more compositions selected from the group consisting of Donepezil, Rivastigmine, Galantamine, Tacrine, Memantine, Vitamin E, CERE-110, LY450139, Exenatide, Varenicline, PF-04360365, Resveratrol, Carbidopa/levodopa immediate-release, Carbidopa/levodopa oral disintegrating, Carbidopa/levodopa/Entacapone, Ropinirole, Pramipexole, Rotigotine, Apomorphine, Selegiline, Rasagiline, Zydis selegiline HCL Oral disintegrating, Entacapone, Tolcapone, Amantadine, Trihexyphenidyl, Benztropine, IPX066, ioflupane 123I, safinamide, Pioglitazone, riluzole, Lithium carbonate, Arimoclomol, Creatine, Tamoxifen, Mecobalam in, tauroursodeoxycholic acid, Idebenone, Coenzyme Q, 5-hydroxytryptophan, Propranolol, Enalapril, Lisinopril, Digoxin, Erythropoietin, Lu AA24493, Deferiprone, IVIG, EGb 761, Avonex, Betaseron, Extavia, Rebif, Glatiramer, Fingolimod, Natalizumab, Mitoxantrone, baclofen, tizanidine, methylprednisolone, CinnoVex, ReciGen, Masitinib, Prednisone, Interferon beta 1a, Interferon beta 1b, ELND002, Tetrabenazine, haloperidol, clozapine, clonazepam, diazepam, escitalopram, fluoxetine, sertraline, valproic acid, divalproex, lamotrigine, Dimebon, AFQ056, Ethyl-EPA, SEN0014196, sodium phenylbutyrate, citalopram, ursodiol, minocycline, remacemide, mirtazapine, Quinacrine, Ascorbic acid, PXT3003, Armodafinil, Ramelteon, Davunetide, Tideglusib, alpha-lipoic acid/L-acetyl carnitine, Niacinamide, Oxybutinin chloride, Tolterodine, Botulinum toxin, and combinations thereof. 4. The method according to claim 1, wherein the subject is a mammal. 5. The method according to claim 4, wherein the mammal is selected from the group consisting of humans, veterinary animals, and agricultural animals. 6. The method according to claim 5, wherein the subject is a human.

Details for Patent 10,597,381

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993		2032-04-02
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2032-04-02
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2032-04-02
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012		2032-04-02